Sequential portal and arterial revascularization (SPAr) is the most common method of graft reperfusion at liver transplantation (LT), contemporaneous portal and arterial revascularization (CPAr) was used to reduce arterial ischemia to the bile ducts. Aim of this pilot study is to prospectively compare SPAr (group 1 #38) versus CPAr (group 2 #42) in 80 consecutive LTs. Biliary anastomosis was always duct to duct [T-tube in 21 % of cases (p = 0.83) in both groups]. CPAr had longer warm ischemia 61 ± 10 versus 39 ± 13 min, p < 0.0001, while SPAr had longer arterial ischemia 96 ± 39 min (p = 0.0001). No PNF while DGF was encountered in 10 versus 5 % (p = 0.32). One-year graft and patient's survival were respectively 87 versus 93 % and 83 versus 88 % in groups 1 and 2 (p = 0.31 and p = 0.39). At a median follow-up of 19 ± 8 versus 17 ± 8 months (p = 0.24), biliary complications were 28 %, being 39 % in group 1 and 19 % in group 2 (p = 0.04). Anastomotic stenoses were present in 11 versus 12 % (p = 0.84), biliary leakage in 5 versus 5 % (p = 0.72) and intrahepatic non-anastomotic biliary strictures in 23 versus 0 % (p = 0.0008) in groups 1 and 2. CPAr is safe and feasible and reduces the incidence of intrahepatic biliary strictures by decreasing the duration of arterial ischemia to the intrahepatic bile ducts.

Hepatocellular carcinoma (HCC is the fifth most common cause of mortality worldwide and\ud the third cancer related cause and is responsible for about 1 million deaths yearly [1]. The ageadjusted\ud worldwide incidence is 5.5-14.9 per 100.000 population. In some areas of the world,\ud such as sub-Saharan Africa and Southeast Asia, HCC represents the first cause of cancer death\ud with an incidence of 52 per 100.000. Furthermore, in Europe and USA, HCC incidence has\ud progressively raised in the past decade representing a burden problem.\ud HCC is one of the few cancers for which a number of risk factors are known in great detail [2,\ud 3]. HCC is almost always (80%) associated with cirrhosis, at least in developed countries, and\ud chronic hepatitis C and B infection, alcoholic cirrhosis and haemocromatosis are some of the\ud established risk factors [4]. The metabolic syndrome related to hypertension, central obesity,\ud diabetes and obesity has been identified as a new risk factor. As a result, screening programs\ud have developed, with the use of ultrasound and α-fetoprotein (AFP), with a hope to increase\ud the chances of diagnosing small HCC and unltimately increase the rate of curability.\ud Definitive diagnosis relies on the demonstration of a typical vascular pattern per liver imaging\ud techniques (triple-phase CT-scan or MRI) of tumors larger than 2 cm with arterial hypervascularity\ud and venous wash- out. Nodules, smaller than 2 cm, should be rechecked every six months\ud or, if highly suspect, subjected to needle biopsy. It’s likely that the study of tumor-specific tissue\ud markers with prognostic value could introduce a systematic use of needle biopsy.\ud Over the past 20 years, surgical treatment of hepatocellular carcinoma has seen an immense\ud boost and improvement, with good survival outcomes and reduced morbidity and mortality.Liver resection (LR) and orthotopic liver transplantation (OLT) and ablative therapies are now\ud considered the only potentially curative treatments for this cancer. LR has achieved improvement\ud in survival within the past decade as a result of advances in diagnosis, surgical management\ud of HCC and perioperative care. However, the long-term prognosis remains poor, and\ud the 5-year overall survival rate ranges between 33% and 44%, with a 5-year cumulative\ud recurrence rate of 80% to 100%.\ud OLT could be viewed as the optimal treatment for HCC that is accompanied by advanced\ud cirrhosis because of the widest possible resection margins for tumour and for a definitive cure\ud of cirrhosis and its related complications. OLT for HCC performed within well-defined\ud oncologic criteria (Milan criteria “reference”) has shown long-term results comparable with\ud those of transplantation for non-HCC patients. However, the critical shortage of available\ud donated organs, together with the increasing number of patients awaiting transplantation,\ud makes this therapeutic option available to only a small percentage of patients. Owing to the\ud limited organ supply, many liv...